Table 5.

Odds Ratios (OR) for Clinical Outcomes by Standard Care With IV Thrombolysis Compared to Without IV Thrombolysis After Excluding Patients Who Received the Low‐Dose tPA (0.6 mg/kg)

	mRS Score of 0 to 1 at 3 Months			Symptomatic HT*			Death at 3 Months*
	OR	95% CI	P Value	OR*	95% CI	P Value	OR*	95% CI	P Value
Crude analysis	0.88	0.60 to 1.31	0.53	7.08	1.69 to 28.24	0.007	0.72	0.08 to 2.94	0.97
PS matching*	1.81	1.06 to 3.08	0.03	6.14	0.93 to Infinity	0.116	0.31	0.01 to 2.82	0.50
PS matching with additional adjustments*	2.00	1.14 to 3.51	0.016	3.79	0.48 to Infinity	0.29	0.48	0.01 to 5.03	0.89

PS‐matched sample included 117 pairs with 1:1 in 50 pairs and 1:2 in 67 pairs. HT indicates hemorrhagic transformation; IV, intravenous; mRS, modified Rankin disability scale; NIHSS, National Institutes of Health Stroke Scale; PS, propensity score; tPA, tissue plasminogen activator.

^*For the symptomatic HT and 3‐month mortality, exact logistic regression analyses were performed.

^*Adjusted for age, sex, baseline NIHSS score, and onset to arrival time.

^*Adjusted for age, NIHSS, and total cholesterol.